Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

Inclusion Criteria: * Age ≥ 18 at the time of screening; * Histological or cytological confirmation of advanced malignancy ; * Progressive cancer at the time of study entry; * Adequate organ and marrow function as defined by the protocol; * Homologous recombination repair gene mutation. Exclusion Criteria: * Major surgery within 4 weeks of the first dose of study treatment. * Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of \>10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded. * Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).